Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2012 1
2015 1
2017 1
2018 2
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines.
Cozzani E, Marzano AV, Caproni M, Feliciani C, Calzavara-Pinton P; Cutaneous Immunology group of SIDeMaST. Cozzani E, et al. G Ital Dermatol Venereol. 2018 Jun;153(3):305-315. doi: 10.23736/S0392-0488.18.06006-6. Epub 2018 Mar 30. G Ital Dermatol Venereol. 2018. PMID: 29600832 Free article.
Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study.
Bardazzi F, Filippi F, Chessa MA, Iommi M, Loi C, Campanati A, Rizzetto G, Tagliati C, Atzori L, Muratori S, Genovese G, Gisondi P, Schena D, Balestri R, Rech G, Feliciani C, Lasagni C, Bigi L, De Simone C, Di Zenzo G, Moro F, Borghi A, Di Lernia V, D'Arrigo G, Tripepi G, Gori M, Pitino A. Bardazzi F, et al. J Eur Acad Dermatol Venereol. 2022 Dec;36(12):2473-2481. doi: 10.1111/jdv.18441. Epub 2022 Sep 10. J Eur Acad Dermatol Venereol. 2022. PMID: 35857348
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
Galluzzo M, Talamonti M, Bernardini N, Chiricozzi A, De Simone C, Bonifati C, Bruni P, Diotallevi F, Esposito M, Graceffa D, Hansel K, Loconsole F, Moretta G, Mugheddu C, Papini M, Richetta A, Skroza N, Atzori L, Fargnoli MC, Persechino S, Offidani A, Stingeni L, Peris K, Potenza C, Bianchi L. Galluzzo M, et al. Expert Opin Biol Ther. 2022 Dec;22(12):1585-1592. doi: 10.1080/14712598.2022.2090835. Epub 2022 Jun 22. Expert Opin Biol Ther. 2022. PMID: 35708257
Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study.
Campanati A, Atzori L, Potenza C, Damiani G, Bianchi L, Corazza M, Tiberio R, Prignano F, Argenziano G, Fargnoli MC, Stingeni L, Mazzotta A, De Pità O, Mazzatenta C, Feliciani C, Donini M, Offidani A, Peris K; LION study group. Campanati A, et al. Dermatol Ther. 2021 Sep;34(5):e15077. doi: 10.1111/dth.15077. Epub 2021 Aug 9. Dermatol Ther. 2021. PMID: 34333823 Free PMC article.
Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.
Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, Marrosu MG, Martinelli V, Milani N, Moiola L, Patti F, Pozzilli C, Trojano M, Zaffaroni M, Comi G; ITEMS (Immunomodulatory Treatment of Early-onset MS) Group. Ghezzi A, et al. Neurol Sci. 2009 Jun;30(3):193-9. doi: 10.1007/s10072-009-0083-1. Epub 2009 Apr 22. Neurol Sci. 2009. PMID: 19387545 Clinical Trial.
Regular wine consumption in chronic heart failure: impact on outcomes, quality of life, and circulating biomarkers.
Cosmi F, Di Giulio P, Masson S, Finzi A, Marfisi RM, Cosmi D, Scarano M, Tognoni G, Maggioni AP, Porcu M, Boni S, Cutrupi G, Tavazzi L, Latini R; GISSI-HF Investigators. Cosmi F, et al. Circ Heart Fail. 2015 May;8(3):428-37. doi: 10.1161/CIRCHEARTFAILURE.114.002091. Epub 2015 Apr 29. Circ Heart Fail. 2015. PMID: 25925415 Free article. Clinical Trial.
Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial.
Dauriz M, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP; GISSI‐HF Investigators. Dauriz M, et al. J Am Heart Assoc. 2017 Jul 5;6(7):e005156. doi: 10.1161/JAHA.116.005156. J Am Heart Assoc. 2017. PMID: 28679559 Free PMC article. Clinical Trial.
Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivellese AA, Squatrito S, Riccardi G; TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial). Vaccaro O, et al. Nutr Metab Cardiovasc Dis. 2012 Nov;22(11):997-1006. doi: 10.1016/j.numecd.2012.09.003. Epub 2012 Oct 11. Nutr Metab Cardiovasc Dis. 2012. PMID: 23063367 Free article. Clinical Trial.